<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title><![CDATA[Cosper Pharma Tech Co., Ltd.]]></title><category><![CDATA[Cosper Pharma Tech Co., Ltd.]]></category><description><![CDATA[Cosper on luotettava kiinalainen lääkevalmistaja, joka tarjoaa CRO/CDMO-palveluita, API:ita ja välituotteita. GMP-sertifioitu tehdas, joka toimittaa koko ketjun tuotekehityksestä tuotantoon. Ota meihin yhteyttä nyt.]]></description><link><![CDATA[https://fi.cosperpharma.com]]></link><language>fi</language><pubDate>Tue, 18 Aug 2026 05:13:47 GMT</pubDate><lastBuildDate>Tue, 18 Aug 2026 05:13:47 GMT</lastBuildDate><item><title><![CDATA[Daridoreksanttihydrokloridin COA]]></title><link><![CDATA[https://fi.cosperpharma.com/news/daridorexant-hydrochloride.html]]></link><pubDate><![CDATA[Fri, 14 Aug 2026 09:47:21 GMT]]></pubDate></item><item><title><![CDATA[Iminesiru Relebactamille]]></title><link><![CDATA[https://fi.cosperpharma.com/news/iminesiru-for-relebactam.html]]></link><pubDate><![CDATA[Fri, 14 Aug 2026 03:33:50 GMT]]></pubDate></item><item><title><![CDATA[Trofinetidin kokidemuodon seulontatutkimus]]></title><link><![CDATA[https://fi.cosperpharma.com/news/screening-study-of-trofinetide-cocrystal-form.html]]></link><pubDate><![CDATA[Wed, 12 Aug 2026 02:38:02 GMT]]></pubDate></item><item><title><![CDATA[JACS: Merck on tehnyt yhteisty&#246;t&#228; Huanquanin ja Conquer Biotechin kanssa julkistaakseen MK-0616:n koko synteesiprosessin.]]></title><link><![CDATA[https://fi.cosperpharma.com/news/jacs-merck-has-partnered-with-huanquan-and-conquer-biotech-to-publicly-disclose-the-total-synthesis-process-for-mk-0616.html]]></link><pubDate><![CDATA[Mon, 10 Aug 2026 09:50:59 GMT]]></pubDate></item><item><title><![CDATA[Miten kelatoivia aineita tulisi valita kohdennetuille radionuklideille?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/how-should-chelating-agents-be-selected-for-targeted-radionuclides.html]]></link><pubDate><![CDATA[Wed, 05 Aug 2026 09:17:22 GMT]]></pubDate></item><item><title><![CDATA[Eutektinen teknologia: Oven avaaminen uusille l&#228;&#228;kkeille ja muunneltujen l&#228;&#228;kkeiden tutkimukselle ja kehitykselle]]></title><link><![CDATA[https://fi.cosperpharma.com/news/eutectic-technology-opening-the-door-to-new-drug-and-modified-drug-r-d.html]]></link><pubDate><![CDATA[Tue, 04 Aug 2026 03:03:10 GMT]]></pubDate></item><item><title><![CDATA[Farmaseuttiset v&#228;lituotteet]]></title><link><![CDATA[https://fi.cosperpharma.com/news/pharmaceutical-intermediate-information.html]]></link><pubDate><![CDATA[Tue, 28 Jul 2026 03:47:46 GMT]]></pubDate></item><item><title><![CDATA[Eli Lillyn avainl&#228;&#228;kkeen: Tirtsepatidin synteesiprosessin analyysi]]></title><link><![CDATA[https://fi.cosperpharma.com/news/analysis-of-the-synthesis-process-for-eli-lilly-s-key-drug-tirzepatide.html]]></link><pubDate><![CDATA[Mon, 27 Jul 2026 06:52:33 GMT]]></pubDate></item><item><title><![CDATA[Trofinetiden synteettinen reitti]]></title><link><![CDATA[https://fi.cosperpharma.com/news/synthetic-route-of-trofinetide.html]]></link><pubDate><![CDATA[Fri, 24 Jul 2026 08:39:34 GMT]]></pubDate></item><item><title><![CDATA[Cagrilintide-valmisteen valmistusmenetelm&#228;]]></title><link><![CDATA[https://fi.cosperpharma.com/news/preparation-method-of-cagrilintide.html]]></link><pubDate><![CDATA[Thu, 16 Jul 2026 03:36:35 GMT]]></pubDate></item><item><title><![CDATA[Maailman ensimm&#228;inen paikallisesti k&#228;ytett&#228;v&#228; JAK-inhibiittori &quot;k&#228;siihottuman&quot; hoitoon – Delgocitinib-voide]]></title><link><![CDATA[https://fi.cosperpharma.com/news/the-world-s-first-topical-jak-inhibitor-for-treating-hand-eczema-delgocitinib-cream.html]]></link><pubDate><![CDATA[Tue, 14 Jul 2026 05:53:02 GMT]]></pubDate></item><item><title><![CDATA[Teko&#228;lyyn perustuva kelaattoreiden suunnittelu ydinl&#228;&#228;kekehitykseen: haasteita]]></title><link><![CDATA[https://fi.cosperpharma.com/news/ai-driven-design-of-chelators-for-nuclear-drug-development-challenges.html]]></link><pubDate><![CDATA[Fri, 10 Jul 2026 06:25:33 GMT]]></pubDate></item><item><title><![CDATA[Suositus brexpipratsolin kehitt&#228;mis- ja synteesireitille]]></title><link><![CDATA[https://fi.cosperpharma.com/news/recommendation-for-the-development-and-synthesis-route-of-brexpiprazole.html]]></link><pubDate><![CDATA[Thu, 09 Jul 2026 08:32:44 GMT]]></pubDate></item><item><title><![CDATA[Influenssa A:n ihmel&#228;&#228;ke – Baloxavir marboxil]]></title><link><![CDATA[https://fi.cosperpharma.com/news/the-miracle-drug-for-influenza-a-baloxavir-marboxil.html]]></link><pubDate><![CDATA[Tue, 07 Jul 2026 07:54:05 GMT]]></pubDate></item><item><title><![CDATA[Virusl&#228;&#228;ke: Amenamevir]]></title><link><![CDATA[https://fi.cosperpharma.com/news/antiviral-drug-amenamevir.html]]></link><pubDate><![CDATA[Fri, 03 Jul 2026 09:43:22 GMT]]></pubDate></item><item><title><![CDATA[Vibegron: hankeehdotus ja synteesireitti]]></title><link><![CDATA[https://fi.cosperpharma.com/news/vibegron-project-proposal-and-synthesis-route.html]]></link><pubDate><![CDATA[Tue, 30 Jun 2026 08:34:43 GMT]]></pubDate></item><item><title><![CDATA[Ikatibanttiasetaatin yleiskatsaus ja valmistus]]></title><link><![CDATA[https://fi.cosperpharma.com/news/overview-and-preparation-of-icatibant-acetate.html]]></link><pubDate><![CDATA[Tue, 30 Jun 2026 08:33:59 GMT]]></pubDate></item><item><title><![CDATA[Syv&#228;llinen artikkeli: N-metylaatio, α-metylaatio, D-aminohapot, polypeptidin ei-luonnolliset aminohapot]]></title><link><![CDATA[https://fi.cosperpharma.com/news/in-depth-article-n-methylation-methylation-d-amino-acids-unnatural-amino-acids-for-polypeptide.html]]></link><pubDate><![CDATA[Tue, 09 Jun 2026 09:55:58 GMT]]></pubDate></item><item><title><![CDATA[Miksi pralatreksaatti on t&#228;rke&#228; nykyaikaisessa sy&#246;v&#228;nhoidossa?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/why-is-pralatrexate-important-in-modern-cancer-treatment.html]]></link><pubDate><![CDATA[Tue, 02 Jun 2026 06:09:11 GMT]]></pubDate></item><item><title><![CDATA[Miten MAAA-1162a syntetisoidaan?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/how-is-maaa-1162a-synthesized.html]]></link><pubDate><![CDATA[Fri, 29 May 2026 10:08:20 GMT]]></pubDate></item><item><title><![CDATA[Dokserkalsiferolin synteesi]]></title><link><![CDATA[https://fi.cosperpharma.com/news/the-synthesis-of-doxercalciferol.html]]></link><pubDate><![CDATA[Thu, 28 May 2026 09:36:32 GMT]]></pubDate></item><item><title><![CDATA[Onko sakkaroosioktasulfaatti-alumiinikompleksi (Orforglipron-ep&#228;puhtaus 18) -viitestandardi tarpeeksi kest&#228;v&#228;, kun GLP-1-s&#228;&#228;ntelypalkit on asetettu 0,1 %:n tunnistuskynnykseen?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/with-glp-1-regulatory-bars-set-at-a-0-1-identification-threshold-is-your-sucrose-octasulfate-aluminum-complex-orforglipron-impurity-18-reference-standard-robust-enough-for-forced-degradation-and-anda-filing.html]]></link><pubDate><![CDATA[Thu, 28 May 2026 03:17:40 GMT]]></pubDate></item><item><title><![CDATA[Miten Migalastat muuttaa Fabryn taudin hoidon?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/how-does-migalastat-transform-fabry-disease-treatment.html]]></link><pubDate><![CDATA[Tue, 26 May 2026 02:25:14 GMT]]></pubDate></item><item><title><![CDATA[Biokatalyyttiset kaskadit mahdollistavat makrosyklisen peptidin Enlicitiden valmistuksen]]></title><link><![CDATA[https://fi.cosperpharma.com/news/biocatalytic-cascades-enable-the-manufacturing-of-the-macrocyclic-peptide-enlicitide.html]]></link><pubDate><![CDATA[Thu, 21 May 2026 09:36:41 GMT]]></pubDate></item><item><title><![CDATA[Mik&#228; tekee osimertinibist&#228; l&#228;pimurtohoidon nykyaikaisessa keuhkosy&#246;v&#228;n hoidossa?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/what-makes-osimertinib-a-breakthrough-therapy-for-modern-lung-cancer-treatment.html]]></link><pubDate><![CDATA[Mon, 18 May 2026 03:09:49 GMT]]></pubDate></item><item><title><![CDATA[Mik&#228; tekee sapropteriinista t&#228;rke&#228;n PKU:n hallinnassa?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/what-makes-sapropterin-important-for-managing-pku.html]]></link><pubDate><![CDATA[Wed, 13 May 2026 05:49:25 GMT]]></pubDate></item><item><title><![CDATA[Mik&#228; on pralatreksaatti?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/what-is-pralatrexate.html]]></link><pubDate><![CDATA[Mon, 11 May 2026 07:02:10 GMT]]></pubDate></item><item><title><![CDATA[Mik&#228; Zanubrutinib on?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/what-is-zanubrutinib.html]]></link><pubDate><![CDATA[Mon, 11 May 2026 07:02:50 GMT]]></pubDate></item><item><title><![CDATA[Mitk&#228; ovat karfiltsomibin vaikutukset ja teho?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/what-are-the-effects-and-efficacy-of-carfilzomib.html]]></link><pubDate><![CDATA[Mon, 11 May 2026 07:03:43 GMT]]></pubDate></item><item><title><![CDATA[Mik&#228; on utpatinib?]]></title><link><![CDATA[https://fi.cosperpharma.com/news/what-is-utpatinib.html]]></link><pubDate><![CDATA[Mon, 11 May 2026 07:04:21 GMT]]></pubDate></item></channel></rss>